Weight Loss News

Diet Drug Acomplia Got Breather in Europe

26 June 2007

Often distinguished as rimonabant, Diet drug Acomplia now can heave a sigh of relief, at least for the moment as the European regulators have decided to review the data on the drug and will discuss the matter in their July meeting scheduled to be held on July 16th to July 19.

The Committee for Medicinal Products for Human Use of the European Medicines Agency, which earlier permitted the diet drug to be sold in Europe over a year back said at their June meeting organized this week that it will carry on the review of the data furnished by the maker on diet drug acomplia, which has been bought by over 100,000 Europeans.

During its meeting on diet drug, the agency also considered the overwhelming vote of the U.S. Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee against acomplia approval for sale in the United States based on the safety data available at present

The advisory panel's vote was based on the new data provided by the FDA staff including data based on the post-marketing reports centered on the drug's usage in Europe. And it is estimated that the FDA will consider its Panel's recommendations in the upcoming several weeks.

Though Acomplia for the moment will be available for purchase in the European Union countries, the EMEA is estimated to carry on the hearing pertaining to the neurological and psychiatric side effects of the drug, comprising depression and suicidality.